The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s top story came from women’s health, as Bayer paved the way for… Read More
News round-up for 27 – 31 October by Bruno Quinney, Content Team at DDW. Women’s health is top of this week’s agenda, as Bayer paves the way for a new approach to treat hot flashes due to menopause. Elsewhere, an anti-obesity medication has health benefits beyond weight… Read More
The US Food and Drug Administration (FDA) has approved Lynkuet (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause. Inhibition of Substance P… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. There have been some ground-breaking advances in women’s health this week, with new treatments… Read More
News round-up for 18-22 December by DDW Digital Content Editor Diana Spencer. There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer. In… Read More
Astellas’ Veoza (fezolinetant) will soon be available to some women in the UK suffering from vasomotor symptoms (VMS) associated with menopause following approval by the Medicines and Healthcare Regulatory Agency (MHRA). Despite VMS, or hot flushes, being a common symptom of menopause, until now, hormone replacement… Read More
